Strategic Information for the Life Science and Analytical Instrument Industry
As the stock market continues its gyrations this year in the face of the unprecedented circumstances of COVID-19 and subsequent macroeconomic downtown, how are life science tool companies’ stocks doing? One way to answer this question is to look at companies that have completed IPOs over the past two years. New to the public market […]
Published this month, the National Science Foundation’s (NSF’s) review of US business R&D spending in 2018 indicates the robust contribution of business R&D to the economy and the diversity of industries conducting R&D in the US. It also lays out the importance of both manufacturing and non-manufacturing R&D to innovation. Top Spending Total US businesses’ […]
A new consensus report, “Genomic Epidemiology Data Infrastructure Needs for SARS-CoV-2: Modernizing Pandemic Response Strategies,” from the National Academy of Sciences offers recommendations to address the SARS-CoV-2 pandemic through the integration of genomic, clinical and epidemiological data. The main focus of the report is how viral sequencing is being utilized to address COVID-19 and the […]
As the number of biotech drugs in development grows exponentially, lab protein and cell purification workflows are facing increasing demand. Such workflows include clone selection, cell expansion studies and recombinant protein isolation prior to analysis. Suppliers of filtration and clarification consumables have responded by innovating to accelerate these workflows. Pall, one of the largest suppliers […]
The National Instituts of Health (NIH) has released the “2020–2030 Strategic Plan for NIH Nutrition Research,” developed by the NIH Nutritional Research Task Force. The report calls for research investments in Precision Nutrition. Unlike personalized nutrition or nutrigenomcis, Precision Nutrituion encompasses both internal and external contributions: diet, genetics, physical health, microbiome, metabolism, dietary habits, activity […]
In the IBO blog’s fourth look at coronavirus-related R&D funding, the focus is on announcements made in May. Governments continue to make large commitments, with funding ultimately designated for universities, research institutes, the private sector, and infectious disease research organizations that will coordinate efforts to funnel money to all three sectors. These organizations include CEPI […]
This is the third of IBO’s review of R&D investments related to COVID-19 (see March 27 and April 17). The outbreak has triggered a wide range of responses spanning immediate and long-term solutions. For R&D, spending priorities range from areas such as new diagnostic approaches and vaccine development to basic research in fields such as […]
Marking another new step forward in more effective COVID-19 testing, as of April 2, the US FDA had approved three molecular point-of-care (POC) tests for COVID-19. The POC assays enable testing in patient care settings such as doctors’ offices and urgent care facilities. POC tests are one of the urgently needed solutions to address the […]
Selected March 2020 COVID-19 Related R&D Funding Announcements Source Recipients Amount Details France National Research Agency and others €5 billion ($5 billion) The investment marks increase over 10 years to the country’s science budget. According to Reuters, 20% will go towards preparing for possible future epidemics. The funding encompasses €50 million ($54 million) in emergency […]
